Randall Holcombe, MD Email Randall Holcombe
- ADJUNCT PROFESSOR | Medicine, Hematology and Medical Oncology
In the News
Dr. Holcombe discusses treatment of colon cancer in The Daily News feature The Daily Check Up.
- Anal Cancer
- Colon Cancer
- Esophageal Cancer
- Gastric (Stomach) Cancer
- Liver Cancer
- Pancreatic Cancer
- Rectal Cancer
Best Doctors in America: 2005-2010; 2011-2015
Dr Holcombe's Research Interests
1. Colon cancer prevention: Colon cancer is the third leading cause of cancer death for both men and women in the United States. Preventing this disease through the development of novel agents, many of them derived from naturally occurring compounds, is an area of specific interest. These compounds are undergoing testing both in the laboratory and in pilot clinical trials.
2. Wnt Signaling in Cancer: The Wnt signal transduction pathway is critical for the development and progression of many cancers but colon cancer in particular. Laboratory research is ongoing which will define the role of specific components of the Wnt signaling pathway in colon cancer and define mechanisms by which activation of this pathway contributes to a malignant phenotype. These studies are performed with an eye toward the development of new diagnostic tests, validation of new prognostic markers, and implementation and testing of novel targeted therapeutic interventions.
3. Clinical and Translational Research: Dr. Holcombe’s major focus has been on the development of hypothesis-driven, investigator-initiated trials in the area of gastrointestinal malignancies. Currently, Dr. Holcombe has several clinical trials in development for the treatment of patients with colon cancer and other gastrointestinal malignancies.
4. Health Services and Healthcare Quality: Transitioning oncology care to value-based paradigms is essential and an area of research focus over the past several years. Dr. Holcombe has published numerous manuscripts related to healthcare quality and novel models of care delivery.
Najdi R, Syed A, Arce L, Theisen H, Ting JH, Atcha F, Nguyen AV, Martinez M, Holcombe RF, Edwards RA, Marsh JL, Waterman ML. A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer. Oncogene 2009 Nov; 28(47).
Nguyen AV, Albers CG, Holcombe RF. Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. International journal of molecular medicine 2010 Jul; 26(1).
Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. Journal of carcinogenesis 2011; 10.
Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer chemotherapy and pharmacology 2011 Aug; 68(2).
Planutiene M, Planutis K, Holcombe RF. Lymphoid enhancer-binding factor 1, a representative of vertebrate-specific Lef1/Tcf1 sub-family, is a Wnt-beta-catenin pathway target gene in human endothelial cells which regulates matrix metalloproteinase-2 expression and promotes endothelial cell invasion. Vascular cell 2011; 3.
Martinez M, Ono N, Planutiene M, Planutis K, Nelson EL, Holcombe RF. Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer cell international 2012; 12(1).
Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ, Holcombe RF. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecologic oncology 2012 Aug; 126(2).
Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 2014 Sep; 74(3).
Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert review of anticancer therapy 2012 Jan; 12(1).
Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma research 2013 Dec; 23(6).
Planutis K, Planutiene M, Nguyen AV, Moyer MP, Holcombe RF. Invasive colon cancer, but not non-invasive adenomas induce a gradient effect of Wnt pathway receptor frizzled 1 (Fz1) expression in the tumor microenvironment. Journal of translational medicine 2013; 11.
Adelson KB, Qiu YC, Evangelista M, Spencer-Cisek P, Whipple C, Holcombe RF. Implementation of electronic chemotherapy ordering: an opportunity to improve evidence-based oncology care. Journal of oncology practice / American Society of Clinical Oncology 2014 Mar; 10(2).
Holcombe RF. Cancer clinical research: return on investment in the era of value-based purchasing. Journal of oncology practice / American Society of Clinical Oncology 2014 Sep; 10(5).
Planutis K, Planutiene M, Holcombe RF. A novel signaling pathway regulates colon cancer angiogenesis through Norrin. Scientific reports 2014; 4.
Alistar A, Sung M, Kim M, Holcombe RF. Clinical pathways for pancreatic neuroendocrine tumors. Journal of gastrointestinal cancer 2012 Dec; 43(4).
Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer chemotherapy and pharmacology 2011 Dec; 68(6).